论文部分内容阅读
目的探讨阿托伐他汀强化治疗对缺血性脑血管疾病患者介入术后血清C反应蛋白(CRP)和D-二聚体水平(D-D)的影响。方法选取2013年3月—2014年3月在钟祥市人民医院住院的缺血性脑血管疾病患者124例,均行全脑血管造影术及支架置入术。采用随机数字表法将所有患者分为对照组和强化组,各62例。对照组患者术后进行常规治疗并口服阿托伐他汀20 mg/d,强化组患者进行常规治疗并口服阿托伐他汀80 mg/d。比较两组患者术前及术后1、3、6个月血清CRP和D-D水平,术后脑血管疾病及血管再狭窄情况。结果两组患者术前血清CRP和D-D水平比较,差异均无统计学意义(P>0.05);病例组患者术后1、3、6个月血清CRP和D-D水平均低于对照组(P<0.05)。强化组患者术后脑血管疾病、血管再狭窄率均低于对照组(P<0.05)。结论阿托伐他汀强化治疗可降低缺血性脑血管疾病患者介入术后血清CRP和D-D水平,有利于减轻炎性反应,改善凝血功能,减少术后脑血管疾病、血管再狭窄的发生。
Objective To investigate the effects of atorvastatin on serum C-reactive protein (CRP) and D-dimer level (D-D) after PCI in patients with ischemic cerebrovascular disease. Methods 124 patients with ischemic cerebrovascular disease who were hospitalized in Zhongxiang People’s Hospital from March 2013 to March 2014 were enrolled in this study. Cerebral angiography and stenting were performed. All patients were divided into control group and intensive group by random number table method, each 62 cases. The patients in the control group were treated routinely and were given atorvastatin 20 mg / d orally. Patients in the intensive group were treated routinely and atorvastatin 80 mg / d orally. The levels of serum CRP and D-D, postoperative cerebrovascular disease and restenosis were compared between the two groups before and 1, 3 and 6 months after operation. Results There was no significant difference in serum CRP and DD levels between the two groups before surgery (P> 0.05). The levels of CRP and DD in the patients in the two groups were lower than those in the control group (P < 0.05). In the intensive group, postoperative cerebrovascular disease and vascular restenosis rate were lower than those in the control group (P <0.05). Conclusions Intensive treatment with atorvastatin can reduce serum CRP and D-D levels after PCI in patients with ischemic cerebrovascular diseases. It is helpful to reduce inflammatory reaction, improve coagulation function, reduce postoperative cerebrovascular disease and restenosis.